Treatment for advanced lung cancer with lung scarring
Treatments studied
Part of Lungs & breathing clinical trials.
This trial tests a treatment for people with advanced non-small cell lung cancer who also have interstitial lung disease (a type of lung scarring). It aims to find out if the treatment is safe and effective for this specific group of patients.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have advanced non-small cell lung cancer (stage IIIB, IIIC, or IV) that cannot be treated with radiation or surgery.
- You must have interstitial lung disease (ILD) confirmed by a special team of lung doctors.
- You must be 18 years or older and have a performance status of 2 or better (meaning you can care for yourself but may not be able to do heavy physical work).
- You must not have certain genetic changes in your tumor (like EGFR, ALK, or ROS) unless the study team agrees.
- You must be willing to use effective birth control if you or your partner could become pregnant, for the duration of the study and 7 months after treatment ends.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new approach for people with certain advanced non-small cell lung cancer (NSCLC) that has spread to lymph nodes in the chest but might still be removed. It combines a short course of high-precision radiation, immunotherapy (sintilimab), and standard chemotherapy before surgery to see if it can improve outcomes.
This trial tests how well chemotherapy works for people with stage IV non-small cell lung cancer that has spread. It is for those who have already tried at least one prior treatment and are healthy enough for more therapy.
This trial tests a pill form of chemotherapy (oral paclitaxel) combined with an immunotherapy drug to keep advanced lung cancer from growing after initial treatment. It may help patients whose cancer was controlled with first-line therapy.
This Phase 2 study tests how results from blood cancer DNA tests (ctDNA) can help choose the best immune therapy approach for newly diagnosed, advanced lung cancer. It aims to improve outcomes by matching treatment decisions to a patient’s immune and blood test “profile.”
This trial tests a combination of ivonescimab and docetaxel for people with advanced non-small cell lung cancer who have had a long response (11-15 months without the cancer getting worse) to first-line immunotherapy. The goal is to see if adjusting treatment based on ctDNA-MRD levels can improve outcomes.
This trial tests a new combination treatment for people with advanced non-small cell or small cell lung cancer that cannot be removed by surgery or cured with standard treatments. It aims to see if the combination is safe and effective.
Hear when a new Non Small Cell Lung Cancer Metastatic trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.